Marianna Sabatino, M.D., Ph.D.
Dr. Sabatino has over 15 years of research experience in multiple scientific disciplines, with 13 years in the cell and gene therapy field. She has built and led Cell, Vector (Lenti and Retro) Process and Analytical Development teams and supported CMC strategy for early and late-stage lifecycle of multiple CAR-T and TCR-T assets including the […]
Sanjeeve Bala, M.D.
Sanjeeve Bala, MD, MPH, joined Neogene as Head, Regulatory Affairs, in September 2022. His industry career began at BeiGene USA, where he served as head of North America/Latin America Regulatory Affairs, developing strategy and overseeing multiple successful submissions to US FDA, HealthCanada, and other global health authorities. Prior to this, Sanjeeve was a Medical Officer […]
Sunny Xie
Sunny Xie is the Vice President of Biometrics at Neogene Therapeutics. Before joining Neogene, Sunny served as VP of Biometrics at OncoSec Medical, where he supported the development of strategy and execution of the immune oncology therapy pIL-12 with electroporation in combination with a checkpoint inhibitor. Before OncoSec, Sunny served as the VP of Biometrics […]
June Seymour, CPA
June A. Seymour, CPA, is the Vice President of Finance at Neogene Therapeutics. Before joining Neogene, Ms. Seymour served as the Executive Director of Finance of Autolus Therapeutics PLC, where she oversaw the scaling of the company’s financial operations, SEC reporting, and Sarbanes Oxley compliance. She was an instrumental part of the teams that led […]
Catherine Lee, J.D.
Catherine Lee, J.D., is the General Counsel at Neogene Therapeutics. She joined Neogene in 2022 with over 20 years of experience, advising public and privately held companies in biotechnology and other industries. Before joining Neogene, Catherine served as the Executive Vice President, General Counsel and Corporate Secretary of Metacrine, Inc., where she provided executive oversight […]
Raphaël Rousseau, M.D, Ph.D.
Raphaël Rousseau, M.D., Ph.D. is the Chief Medical Officer of Neogene Therapeutics. Before joining Neogene, Dr. Rousseau served as Executive Vice President, Head of Product Development, and Chief Medical Officer at Gritstone bio, where he was responsible for the company’s global clinical development strategies and expansion of its neoantigen-based immunotherapies. Prior to Gritstone bio, Dr. […]
Sanne Weijzen, Ph.D.
Sanne Weijzen, Ph.D., is the Vice President, Corporate Strategy and EU Operations at Neogene Therapeutics. Dr. Weijzen has more than 20 years of combined academic and biotech industry experience. Before joining Neogene, she spent 4 years as a COO of Scenic Biotech, where she was responsible for finance, HR, IP and legal, while building the […]
Marisa Leonard
Marisa is the Head of Business Development at Neogene Therapeutics. Prior to joining Neogene, Marisa spent nearly five years at Kite, a Gilead Company, where she worked in Business Development. Marisa worked on the Gilead / Kite acquisition and was responsible for leading cell therapy transactions including partnerships, academic collaborations and outlicenses. Previously, Marisa was […]
Martin Murphy, Ph.D.
Martin Murphy is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 alongside The Wellcome Trust. Since then, Dr. Murphy has been closely involved in the foundation and development of seven Syncona companies, including: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon and Resolution Therapeutics. He is Chairman of Quell Therapeutics […]
Harish Mundre
Harish Mundre is the Vice President, Head of Information Technology at Neogene Therapeutics. In over 20 active years in the tech industry, Mr. Mundre has held several senior roles in notable companies such as Sun Microsystems and Amgen Inc. Before Neogene, he served as a co-founder and CTO of Polar Wave Technologies where he helped […]
